E Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

E Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,683	Closed	-$72.8K	–	508
2026 Q1	$72.8K	Buy	+12,683	New	+$89.9K	﹤0.01%	479

Other funds holding LXEO

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

E Fund Management's LXEO Position: Q2 2026 in Review

E Fund Management sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 12,683 shares — an estimated $72.8K sold.

E Fund Management first reported a position in LXEO in Q1 2026 and held it in 1 quarter. The position peaked at $72.8K in Q1 2026. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

E Fund Management reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
E Fund Management sold 12,683 Lexeo Therapeutics shares in Q2 2026, an estimated $72.8K.
E Fund Management first reported a position in Lexeo Therapeutics in Q1 2026 and held it in 1 quarter.
E Fund Management's Lexeo Therapeutics position peaked at $72.8K in Q1 2026.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.